Clinical Trial: IPX056 (extended-release formulation of baclofen) vs. immediate-release baclofen tablets
| Description | |
|---|---|
| To determine whether an extended-release formulation of baclofen can improve spasticity and related symptoms as compared to immediate-release baclofen in people with MS. | |
| Institution/Location | Contact Information |
| Multicenter Florida Indiana Kansas Michigan Montana New York Texas | Please see listing below for the study site in your state. |
Treatment mode of action: To improve spasticity associated with MS
Institution(s): Multicenter, United States
Type of MS: All types, with spasticity
Number of Subjects: 28
Funding: Impax Pharmaceuticals, a division of Impax Laboratories, Inc.
Study Site Contact List:
Florida
Meridien Research, Tampa FL
lfucheck@meridienresearch.net, (813) 87-STUDY or (813) 877-8839
Indiana
Allied Physicians Inc., Ft. Wayne, IN
Crista Ellias, (260) 460-3257, celias@fwnc.com
Kansas
MidAmerica Neuroscience Institute, Lenexa, KS
Laurie, (913) 894-1500 ext. 166, lkemble@neurokc.com
Michigan
Quest Research Institute, Bingham Farms, MI
(888) QUEST24 or (888) 783-7824, barb@questri.com
Montana
Great Falls Clinic, LLP, Great Falls, MT
(406) 268-3955, connie.winner@gfclinic.com
New York
Empire Neurology, PC, Latham, NY
Judy Button, jbutton@tristateneuro.com
Texas
Central Texas Neurology Consultants, Round Rock, TX
Lori Mayer, (512) 218-1222, centexms@gmail.com